Skip to content
DraconiticResearch
Search Sources API
184,937 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BY 4.0Annals of The Royal College of Surgeons of England

Potential underutilisation of weight loss medications in obese patients with knee osteoarthritis

  • N Badhe1,2
  • C Busby1
  • T Kurien1
  • BA Marson1
  1. 1University of Nottingham, UK
  2. 2University of Cambridge, UK
Read full textDOICite

Abstract

Introduction: Obesity is a major risk factor for knee osteoarthritis (OA), contributing to earlier symptomatic onset, increased pain severity and greater lifetime disability. Despite guidance that weight alone should not limit access to total knee arthroplasty (TKA), body mass index (BMI) thresholds are applied widely in clinical practice. This study investigated the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use among obese OA patients awaiting TKA and evaluated the influence of BMI on access to TKA.

Methods: A 30% random sample of a single-centre TKA waiting list (n = 300) in August 2025 was analysed. Data extracted included age, sex, BMI, time on waiting list, surgical listing status, comorbidities and use of weight loss interventions. Patients were stratified by BMI category (<35, 35–40, >40) and sex.

Results: Median BMI was 33.0 [27.9–38.0], with 120 patients (40%) classified as obese (BMI ≥35). Among obese patients, 45% were initially denied or conditionally listed for surgery, rising to 74.1% for BMI >40. Only 13 obese patients (10.8%) were taking GLP-1 RAs, despite extensive eligibility. Female patients had a higher average BMI (p = 0.049) and faced higher denial rates than male patients (52% vs 28%, p = 0.013). Most obese patients (n = 102) had ≥3 comorbidities, often including diabetes (n = 22) and obstructive sleep apnoea (n = 26).

Conclusion: Current pathways for managing obese patients with knee OA are inadequate. GLP-1 RAs may offer a promising solution to help reduce barriers to surgery. Further research is needed to determine whether GLP-1 RAs could help reduce the progression of OA and need for TKA.

Related

  1. Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications
    S. Athinarayanan, A. R. Zoller, K. E. Bergethon +2
    medRxivPreprintCC BY-NCFull textNutritionmedRxiv
  2. Incidence of venous thromboembolism with intraoperative tranexamic acid use in breast surgery patients on estrogen-containing medications: a case series
    Quentin K. Tsang, Isabella F. Churchill, Precious Adekoya +1
    JPRAS openPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Anti-Obesity Medications Versus Metabolic Bariatric Surgery as Pathways to Heart Transplant Eligibility in LVAD-Supported Patients: A Narrative Review
    Noah Sicouri, Vanesa Brecher, Vasiliki Androutsopoulou +4
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. The use of triptans, opioids, and other rescue medications among patients with migraine prescribed calcitonin gene–related peptide inhibitors for migraine prophylaxis
    Jennifer L. Nguyen, Tiffany Lee, Elizabeth C.S. Swart +4
    Journal of Managed Care & Specialty PharmacyPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  5. Polydeoxyribonucleotide (PDRN) in Osteoarthritis: Immunomodulatory and Matrix-Supportive Potential, A2A Receptor-Associated Mechanisms, and Translational Challenges
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{badhe2026potential,
  title = {{Potential underutilisation of weight loss medications in obese patients with knee osteoarthritis}},
  author = {N Badhe and C Busby and T Kurien and BA Marson},
  journal = {Annals of The Royal College of Surgeons of England},
  year = {2026},
  month = aug,
  doi = {10.1308/rcsann.2026.0063},
  url = {https://doi.org/10.1308/rcsann.2026.0063},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Potential underutilisation of weight loss medications in obese patients with knee osteoarthritis
AU  - N Badhe
AU  - C Busby
AU  - T Kurien
AU  - BA Marson
PY  - 2026
DA  - 2026/08/06
JO  - Annals of The Royal College of Surgeons of England
DO  - 10.1308/rcsann.2026.0063
UR  - https://doi.org/10.1308/rcsann.2026.0063
AB  - Introduction: Obesity is a major risk factor for knee osteoarthritis (OA), contributing to earlier symptomatic onset, increased pain severity and greater lifetime disability. Despite guidance that weight alone should not limit access to total knee arthroplasty (TKA), body mass index (BMI) thresholds are applied widely in clinical practice. This study investigated the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use among obese OA patients awaiting TKA and evaluated the influence of BMI on access to TKA.  Methods: A 30% random sample of a single-centre TKA waiting list (n = 300) in August 2025 was analysed. Data extracted included age, sex, BMI, time on waiting list, surgical listing status, comorbidities and use of weight loss interventions. Patients were stratified by BMI category (<35, 35–40, >40) and sex.  Results: Median BMI was 33.0 [27.9–38.0], with 120 patients (40%) classified as obese (BMI ≥35). Among obese patients, 45% were initially denied or conditionally listed for surgery, rising to 74.1% for BMI >40. Only 13 obese patients (10.8%) were taking GLP-1 RAs, despite extensive eligibility. Female patients had a higher average BMI (p = 0.049) and faced higher denial rates than male patients (52% vs 28%, p = 0.013). Most obese patients (n = 102) had ≥3 comorbidities, often including diabetes (n = 22) and obstructive sleep apnoea (n = 26).  Conclusion: Current pathways for managing obese patients with knee OA are inadequate. GLP-1 RAs may offer a promising solution to help reduce barriers to surgery. Further research is needed to determine whether GLP-1 RAs could help reduce the progression of OA and need for TKA.
SN  - 0035-8843
SN  - 1478-7083
ER  -